Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1.
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-EIF4H, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The eukaryotic translation initiation factor 4H commonly known as eIF4H is an essential protein participating in the initiation phase of protein synthesis. It holds a mass of approximately 27 kDa. eIF4H is expressed in various tissues including the brain liver and muscle. The protein promotes the unwinding of RNA secondary structures aiding ribosome attachment to the mRNA. This function aligns closely with its alternate name eukaryotic translation initiation factor 4H.
Biological function summary
EIF4H enhances the helicase activity of eIF4A an RNA helicase vital for translation initiation. It forms part of the translation initiation complex. The complex brings together eIF4E eIF4G and eIF4A enhancing mRNA recognition and processing. eIF4H stabilizes the eIF4A-mRNA interaction reducing the likelihood of premature dissociation and permitting efficient scanning for the start codon.
Pathways
EIF4H plays a significant role in the mTOR (mechanistic target of rapamycin) signaling pathway which regulates cell growth and proliferation. This pathway influences protein synthesis by controlling the availability and activity of initiation factors like eIF4A and eIF4E. mTOR signaling overlaps with the MAPK (mitogen-activated protein kinase) pathway with eIF4H indirectly interacting with RAF proteins which regulate cell cycle progression and differentiation.
Researchers link eIF4H to neurological disorders like Autism Spectrum Disorder and certain cancers such as glioblastoma. Alterations in the expression or function of eIF4H may impact the mTOR pathway influencing tumor progression and neural development. These dysfunctional roles also involve eIF4E as both proteins contribute to abnormal translation initiation and gene expression in these conditions.
